Shanghai Zhongshan Hospital clinical trial pipeline

5 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 2 with minor changes only.

1. Notable

   Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line…Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

   Primary completion pushed from Jul 31, 2026 to Mar 31, 2027

   Also in this update: Recruitment opened; Study completion pushed from Jul 31, 2026 to Jul 31, 2027

   Shanghai Zhongshan Hospital·Phase 2· NCT07012980· Registry history of NCT07012980 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Notable

   TRACE-pPCI · Trends and Risk Factors of Adverse Cardiovascular…TRACE-pPCI · Trends and Risk Factors of Adverse Cardiovascular and Cerebrovascular Events After Primary PCI

   Recruitment opened

   Also in this update: Start date changed from estimate of Oct 1, 2026 to Sep 28, 2026

   Shanghai Zhongshan Hospital·Not specified· NCT07833995· Registry history of NCT07833995 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

3. Notable

   Mazdutide for Treating PCOS

   Primary completion date changed from estimate of Dec 31, 2025 to Sep 1, 2026

   Also in this update: Trial completed; Final enrollment: 43 participants (planned 50)

   Shanghai Zhongshan Hospital·Phase 1/2· NCT06519656· Registry history of NCT06519656 on ClinicalTrials.gov (opens the registry)

   Sep 21, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.